JDRF Invites TIXiMED Chief Scientific Officer to Speak at Global Type 1 Diabetes Cures Strategy Workshop
JDRF invited Anath Shalev, M.D., the Chief Scientific Officer of TIXiMED, Inc. and the Director of the UAB Comprehensive Diabetes Center, to the Global T1D Cures Strategy Workshop: Genetic Engineering Approaches for T1D Workshop in October of 2023. Shalev gave a talk in a session on Islet Targeting and Beta Cell Regeneration/Survival. She also discussed her work on targeting TXNIP for type 1 diabetes and drug development progress with the oral drug candidate TIX100.
Embassy of Switzerland in the U.S. Invites TIXiMED Chief Scientific Officer to Washington, DC to Pitch Startup
TIXiMED Chief Scientific Officer Interviewed on Taking the Pulse: A Health Care Podcast
Anath Shalev, M.D., the Chief Scientific Officer of TIXiMED, Inc., recently appeared as a guest on Taking the Pulse: A Health Care Podcast. On the podcast, Dr. Shalev, who serves as the Chief Clinical Officer and Director of the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB), discusses recent advancements in type 1 diabetes research as well as cutting-edge treatments and novel drug therapies.
TIXiMED Chief Scientific Officer Chairs Session at the 2023 National Institutes of Health HIRN Meeting
Anath Shalev, M.D., TIXiMED’s Chief Scientific Officer, attended the Human Islet Research Network (HIRN) 2023 Annual Investigator Meeting in September. There, she chaired the session Beta Cells on Target: Small Molecules and Extracellular Vesicles in Type 1 Diabetes. Since 2019, Shalev has served as the chair of the HIRN Consortium on Beta Cell Death and Survival (CBDS).
TIXiMED Chief Scientific Officer Authors Study Published in Diabetes
In a study published in Diabetes, Anath Shalev, M.D. and Guanlan Xu, Ph.D. examine the mechanism underlying verapamil’s beneficial effect on type 1 diabetes. According to Dr. Shalev, the study’s results “reveal IGF-1 signaling as yet another previously unappreciated pathway affected by verapamil and TXNIP that may contribute to the beneficial verapamil effects in the context of Type 1 diabetes.” Dr. Shalev is the Chief Scientific Officer of TIXiMED, Inc., a company developing and commercializing TXNIP inhibiting medications as therapeutics for type 1 and type 2 diabetes.
TIXiMED Chief Scientific Officer Presents at 2023 Immunology of Diabetes Society Congress
Renowned diabetes researcher and Chief Scientific Officer of TIXiMED Dr. Anath Shalev presented her work on verapamil and TXNIP inhibition at the 2023 Immunology of Diabetes Society Congress in Paris.